This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention relates to the use of iodide compounds, to treat and prevent cachexia and cardiotoxicity resulting from treatment with an anti-cancer therapy.

The present invention relates to the use of iodide compounds, to treat and prevent cachexia and cardiotoxicity resulting from treatment with an anti-cancer therapy.

Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.

Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.

The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same.

The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same.

The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same.

The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).